QPPV.COM KNOWLEDGE ASSESSMENT

Apixaban: Discovery, Development, Safety and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Apixaban: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which description best explains how direct factor Xa inhibition reduces clot formation?

It blocks the prothrombinase complex from converting prothrombin to thrombin, reducing downstream fibrin formation. It directly neutralises circulating thrombin and removes fibrin from established clots. It inhibits platelet activation without affecting the coagulation cascade. It increases vitamin K availability and thereby reduces synthesis of coagulation factors.

Question 2 of 10 A reviewer sees apixaban 2.5 mg twice daily and labels it underdosing without further information. What is the main analytical problem?

The numerical dose cannot be interpreted without knowing the indication, treatment phase and applicable dose-selection criteria. Any twice-daily dose below 5 mg is necessarily an error in every indication. A reduced dose is appropriate only when the patient has a low INR. Dose appropriateness is determined only by whether a bleeding event has occurred.

Question 3 of 10 Which conclusion about apixaban's first EU authorisation is accurate?

It was first authorised in the EU for prevention of VTE in adults undergoing elective hip or knee replacement surgery. It was first authorised in the EU for prevention of stroke in all patients with atrial fibrillation. It was first authorised in the EU for acute coronary syndrome in combination with antiplatelet therapy. It was first authorised in the EU for paediatric treatment of venous thrombosis.

Question 4 of 10 A clinician proposes adjusting apixaban doses to achieve a target INR, as is commonly done with warfarin. What is the most appropriate interpretation?

INR-guided titration is the routine apixaban dosing model because both medicines inhibit vitamin K. Apixaban is not routinely managed through INR-guided dose adjustment; dose selection should follow the indication-specific product information. INR is used to determine whether apixaban has been absorbed after every dose. INR-guided dosing is required only when apixaban is prescribed for venous thromboembolism.

Question 5 of 10 A patient taking apixaban starts a strong combined CYP3A4/P-glycoprotein inhibitor and subsequently develops bleeding. Which interaction mechanism is most relevant?

Reduced apixaban exposure, which may permit thrombosis. Direct activation of factor Xa by the inhibitor. Increased apixaban exposure, potentially increasing bleeding risk. A reduction in platelet activity that explains the bleeding.

Question 6 of 10 Which is the most defensible interpretation of ARISTOTLE's finding of less major bleeding with apixaban than with warfarin?

Apixaban cannot cause major bleeding when used at an authorised dose. The comparison establishes that apixaban has lower bleeding risk than every anticoagulant in every population. Apixaban had a more favourable major-bleeding result than warfarin in the studied population, but serious bleeding remained possible. The result means bleeding reports during apixaban treatment should generally be considered unrelated to treatment.

Question 7 of 10 Why should severe hepatic disease with coagulopathy not be treated merely as a straightforward change in apixaban pharmacokinetics?

Hepatic disease may affect drug handling and can also disturb coagulation independently. Hepatic disease always lowers apixaban exposure and therefore rules out bleeding risk. Coagulopathy is relevant only to vitamin K antagonist treatment. Hepatic function has no relevance to anticoagulant safety assessment.

Question 8 of 10 What is the most appropriate interpretation of the financial terms of the Bristol-Myers Squibb–Pfizer alliance for pharmacovigilance governance?

Profit-sharing terms by themselves define each partner's regulatory and case-processing responsibilities. The collaboration makes allocation of safety responsibilities unnecessary. Commercial arrangements do not themselves define pharmacovigilance responsibilities; applicable authorisation and safety arrangements must do so. Each partner's safety responsibilities can be inferred solely from which company discovered the medicine.

Question 9 of 10 What does the failed acute-coronary-syndrome programme contribute to a lifecycle assessment of apixaban?

It is irrelevant because unsuccessful development programmes cannot inform pharmacovigilance. It demonstrates that efficacy in VTE establishes efficacy in acute coronary syndrome. It shows that only pharmacokinetic interactions can cause bleeding with apixaban. It provides evidence that benefit-risk must be assessed by indication and treatment combination, not inferred from success elsewhere.

Question 10 of 10 A patient is discharged after a VTE-related admission with a dose listed but no explanation of when the regimen should change. What is the most relevant pharmacovigilance concern?

The discharge record is adequate because apixaban is always prescribed at one dose. A transition-of-care communication gap could lead to a regimen or treatment-phase error. The omission can be resolved by monitoring INR after discharge. The dose should be inferred from the patient's previous antiplatelet treatment.

Apixaban: Discovery, Development, Safety and Pharmacovigilance — Knowledge Assessment

Cookie Settings